Oncolytics Biotech Inc ONCY

Primary Symbol: T.ONC

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > SP

<< Previous

Bullboard Posts

Next >>

Comment by Snowdrifton Mar 23, 2023 11:29am

146 Views

Post# 35356281

RE:SP

List of failed trials??? They've had nothing but successes.

Big pharma would not hang around for years with a company that had a series of failed trials.

Pretty lame attack on your part.

lonc17 wrote: It's not hard to read the tea leaves here. The share price is cratering weeks before ONC's "big reveal" of key data. And their number 1 prospect declined to make a suitable offer during an exclusivity period.

I suppose Bracelet will be just another on the long list of failed trials for ONC.

Fortunately for Matt, he has the miracle CR from Goblet Panc to keep the gravy train running for another few years.

Unfortunately for any long term shareholder, this will most likely mean another reverse split.

I sincerely hope I am wrong but things are looking very grim for ONC.